Lung Cancer

This study examined the acquired resistance found from treatment with third-generation EGFR TKIs to see if it was associated with diverse pathways, with an eye for the EGFR T790M mutation.

According to researchers, black and Hispanic patients are less likely to undergo guideline recommended PET/CT imaging at NSCLC diagnosis, which could partially explain differences in survival.

This study examined the association of disease progression and the deterioration of health-related quality of life for patients with metastatic breast, pancreatic, lung, and colorectal cancer.

Adults with advanced non-small cell lung cancer and impaired performance status experience significantly shorter survival after treatment with immune checkpoint inhibitors (ICIs) and receive ICIs more often than those with better performance status.

Although accumulating data continue to show immunotherapy as a major step forward in the treatment of patients with non–small cell lung cancer (NSCLC), questions regarding optimal sequencing and treatment duration still remain. At the 17th Annual Winter Lung Cancer Conference®, hosted by Physicians’ Education Resource®, LLC, multiple presentations looked for answers to address these issues.

This study found that carboplatin-pemetrexed treatment followed by pemetrexed maintenance was a valid option for first-line treatment of elderly patients with advanced nonsquamous non-small cell lung cancer.

Janssen Pharmaceutical Companies recently announced the FDA granted breakthrough therapy designation to JNJ-61186372, an EGFR-MET bispecific antibody, for the treatment of metastatic non-small cell lung cancer with EGFR exon 20 mutations.

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.

A study, published in Nature Cancer, demonstrates the quick and evolving revolutions of resistance mechanisms in small cell lung cancer.

Researchers suggested that patients with non-small cell lung cancer (NSCLC) who have higher measures of tumor mutations that appear in a blood test generally have a better clinical response to PD-1-based immunotherapy than those with a lower measure of mutations.

The FDA Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab plus erlotinib demonstrated a favorable benefit and risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer.

LUNGevity Foundation released a Lung Cancer Scorecard to examine how effectively (or ineffectively) states are addressing lung cancer.

The FDA recently granted priority review to Takeda’s supplemental new drug application for brigatinib to treat ALK-positive metastatic non-small cell lung cancer.

Karen Kelly, MD, sat down to discuss her presentation on when to start immunotherapy in a real world, patient setting.

Walter Curran, MD, detailed his presentation on immunotherapy and radiation therapy, and how integrating the 2 treatment options presents an exciting opportunity moving forward.

With February being National Cancer Prevention Month, here are the latest updates in cancer prevention.

Gilberto Lopes, MD, MBA, FAMS, discussed his presentation about when to stop immunotherapy treatments for patients with lung cancer.

Rogerio Lilenbaum, MD, talked about the state of lung cancer in regards to immunotherapy and targeted therapy at the 17th Annual Winter Lung Conference in Miami Beach, Florida.

Roche recently announced the FDA accepted their supplemental biologics license application and granted priority review to atezolizumab for the treatment of non-small cell lung cancer.

The FDA granted a priority review to the new drug application for lurbinectedin as a treatment for patients with small cell lung cancer.

Medical oncologsts discuss the case of a 70-year old woman with synchronous multiple primary lung cancer.

Among participants who were current or former smokers, the NELSON trial found that volume CT screening enabled a significant reduction of harms without jeopardizing favorable outcomes.

The FDA granted a priority review to capmatinib, a MET inhibitor being analyzed for the first-line treatment of previously treated patients with METex14-mutated advanced NSCLC.

In observing individuals aged 65 and older suffering from a recent nonmetastatic cancer, researchers indicated that there is a need to change attitudes toward aging and older people.

The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC.